5:01 PM
 | 
Sep 09, 2009
 |  BC Extra  |  Top Story

Vivus gains on obesity data

Vivus Inc. (NASDAQ:VVUS) jumped $4.89 (71%) to $11.80 on Wednesday after reporting that once-daily oral Qnexa phentermine/topiramate met the primary endpoints in two double-blind, U.S. Phase III trials to treat obesity and weight-related co-morbidities. In the EQUIP trial, both doses of Qnexa (3.75 mg...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >